GHK-Cu and melanotan-2 compared
Skin appearance, hair counts, copper transport, and pigment follow-up answer different questions. The outcome matters as much as the observation period.
The result depends on what was measured
An endpoint is the outcome a study measures. For skin peptides, it might be collagen production in cells, copper passing through tissue, hair counts, or a change in pigmentation. These measurements are useful for different reasons and cannot be arranged into a single ranking of renewal.
The first distinction is the study setting. A laboratory experiment can examine a mechanism under controlled conditions. A trial in people can assess a particular preparation in a defined population. A case report can describe an unexpected event. None of these designs answers every question about a compound.
The second distinction is the substance itself. GHK, GHK-Cu, a preparation containing GHK and another ingredient, and a three-peptide blend are different test materials. A shared word in their names is not evidence that their results transfer.
Copper transport over 48 hours
The 2011 excised-skin experiment measured copper moving through and remaining in human skin outside the body after application as GHK-Cu. The 48-hour observation describes transport and retention in that experimental system.
It does not establish the persistence of intact peptide in a living person. It does not measure wrinkle depth or how long a visible improvement lasts. A retained amount of copper and a lasting cosmetic effect would require different measurements, even if both are relevant to future studies of topical preparations.
A combination hair study over six months
The 2016 trial in 45 men with pattern hair loss tested GHK combined with 5-aminolevulinic acid. Hair-count gains were greater than with placebo during the six-month study. The comparison gives the result more interpretive value than a change reported without a control group.
The trial still belongs to that combination and that population. It cannot isolate GHK's contribution or show that every copper peptide preparation increases hair counts. A question about persistence after stopping also needs later observation; the study period alone does not answer it.
Pigment followed after exposure ended
The 2026 melanotan II case report documented oral pigmentation and subsequent follow-up. Cheek pigment began fading by 28 days after stopping, while lighter gum pigment remained at three months. The observation concerns an unwanted change in one person.
This is valuable safety documentation, but it is not a controlled estimate of how often pigmentation occurs or how quickly it resolves. It also cannot be compared with a hair-count gain as though both were different amounts of the same benefit. The biological outcome and the reason for observing it are different.
GLOW has a different gap
GLOW commonly refers to GHK-Cu, BPC-157, and TB-500 combined. There is no controlled trial establishing the combined blend's efficacy or safety in the sources discussed here. A review of peptide therapies discusses individual compounds and the limits of the wider field.
The mixture therefore has no clinical duration of effect that can be compared with the skin experiment or hair trial. Missing blend data are not a short follow-up period; they are an absence of the relevant controlled study. Ingredient findings cannot fill that gap by addition.
Route and formulation belong in the comparison
The topical GHK review describes skin findings alongside delivery and formulation problems. A topical preparation encounters the skin barrier. An injection introduces different exposures and safety questions. The cosmetic record cannot establish injectable safety.
The FDA's safety-risk material retains concerns about the injectable peptides discussed here. Its withdrawn-nomination wording is not approval or safety clearance. Compounded medicines are not FDA-approved, and a prescription is not evidence that a particular cosmetic or healing claim has been established.
Questions that make a claim assessable
A useful account identifies the exact substance, preparation, route, study population, comparison group, outcome, and length of follow-up. It also states what was not measured. Those details help distinguish a promising mechanism from an established human result.
The compound pages apply those distinctions to GHK-Cu, GLOW, and melanotan-2. The sources describe the studies in their own settings, without treating the number of papers as a measure of clinical certainty.